Logo
x

Search

Subscribe Now

regimen

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

Sanofi's Sarclisa Combination Regimen Receives Health Canada's Approval for Multiple Myeloma

  • October 13, 2021
Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

  • June 16, 2020
Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastric Cancer

Celltrion and MSD Report Results of First-Line Triplet Regimen P-I/II PANTHERA trial in Patients with HER2-Positive Advanced Gastr...

  • May 27, 2020
QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer

QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer

  • April 16, 2020
Janssen's Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma

Janssen's Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multi...

  • October 31, 2019
Merck Receives EU's CHMP Positive Opinion for its Zerbaxa (ceftolozane and tazobactam) and Keytruda (pembrolizumab) + Inlyta (axitinib) Regimen

Merck Receives EU's CHMP Positive Opinion for its Zerbaxa (ceftolozane and tazobactam) and Keytruda (pembrolizumab) + Inlyta (axit...

  • July 30, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.